Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Ashley Bell

Nurse Practitioner, Family Knoxville, TN Nurse Practitioner

NPI 1114562782 CMS profile 11242135

1415 Old Weisgarber Rd Ste 200, Knoxville, TN 37909

Open in the dashboard

General payments

$22,254

1,153 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ashley Bell of Knoxville, TN is reported in the CMS Open Payments database as having received $22,254 across 1,153 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,636 186
2024 General $4,543 220
2023 General $4,466 252
2022 General $4,653 272
2021 General $3,956 223

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ashley Bell
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Ashley Bell were reported at $4,636. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Ashley Bell Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $3,956 $124 $35–$379 $132
2022 $4,653 $141 $44–$430 $149
2023 $4,466 $154 $49–$476 $160
2024 $4,543 $165 $51–$504 $164
2025 $4,636 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novartis Pharmaceuticals Corporation $2,385 71 payments
  2. AstraZeneca Pharmaceuticals LP $1,396 70 payments
  3. Incyte Corporation $1,206 57 payments
  4. Daiichi Sankyo Inc. $1,164 62 payments
  5. Janssen Biotech, Inc. $1,119 56 payments
  6. E.R. Squibb & Sons, L.L.C. $1,036 88 payments
  7. Pfizer Inc. $979 56 payments
  8. Celgene Corporation $848 57 payments
  9. Merck Sharp & Dohme Corporation $775 39 payments
  10. Seattle Genetics, Inc. $764 32 payments
  11. Other $10,581 565 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $19,967 1,126 payments
  2. Long term medical supply or device loan $1,280 13 payments
  3. Education $1,008 14 payments
Products named General payments · program years 2021–2025
  1. KISQALI $1,750 38 payments
  2. ENHERTU $917 47 payments
  3. JAKAFI $762 39 payments
  4. LIBTAYO $728 41 payments
  5. KEYTRUDA $696 35 payments
  6. OPDIVO $669 52 payments
  7. REBLOZYL $594 39 payments
  8. VERZENIO $520 34 payments
  9. DARZALEX $448 25 payments
  10. Lenvima $415 24 payments
  11. Other $19,022 1,055 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

341

Median for Nurse Practitioner: 389

Drug cost

$22,394

Median for Nurse Practitioner: $21,885

Branded share of claims

24%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 28 $17,555
Anastrozole Generic 69 $1,025
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 43 $940
Oxycodone Hcl Generic 37 $817
Hydroxyurea Generic 19 $494
Letrozole Generic 15 $334
Dexamethasone Generic 17 $217
Ondansetron Odt Ondansetron Brand 11 $201
Ondansetron Hcl Generic 13 $199
Prochlorperazine Maleate Generic 11 $164

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 64 billing codes

Paid by Medicare

$67,121

Of which drugs: $60,420

Medicare patients

109

Average age 74

Services billed

6,840

60 women, 49 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Cancer 49%
Diabetes 37%
Chronic kidney disease 36%
Ischemic heart disease 28%
COPD 28%
Depression 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 80 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KISQALI
$534 — —
ENHERTU
$252 — —
REBLOZYL
$216 — —
JAKAFI
$131 — —
Fabhalta
$122 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 80 with Patron

Records

1,153 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record